Plus, news about Opdivo:
📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line non-small cell lung cancer patients …
Senior HHS official and head of Medicare Chris Klomp didn’t mince words when he called competition with China’s ascending biotech industry “a war.” Klomp’s comments,
Biopharma industry representatives are taking issue with some of the FDA’s more political proposals in the next round of user fee agreements, particularly ones that
Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don’t seem to agree.
Milan-based Recordati confirmed Thursday that it has received a buyout offer north of $12 billion. The company said in a press release that private equity
UCB has selected Gwinnett County, GA, as the location for its new biologics factory. The 460,000-square-foot facility is expected to cost $2 billion and will
Plus, news about Opdivo:
📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line non-small cell lung cancer patients …